The U.S. Embassy in Mozambique announces the arrival of 2,016,000 doses of the Johnson&Johnson vaccine that the United States is sharing with the Republic of Mozambique through COVAX. This is the United States’ fourth and largest bi-lateral COVID-19 vaccine delivery to Mozambique, bringing the total number of U.S.-donated vaccines to nearly 3.5 million, and maintaining the United States as Mozambique’s largest bi-lateral vaccine donor.
“The United States remains committed to sharing vaccines equitably, around the world,” U.S. Ambassador to Mozambique Dennis W. Hearne said. “No one is protected from COVID-19 until everyone is vaccinated. As more vaccines become available to all nations around the world, we have a shared interest in getting everyone who is eligible vaccinated.”
The U.S. Government has provided early and ongoing support for the response to the COVID-19 pandemic in Mozambique, including assistance valued at $62.5 million. This assistance includes the recent donation of 60 oxygen cylinders and a PSA oxygen plant, 50 ventilators, personal protective equipment for healthcare workers, laboratory and oxygen equipment, training, and funding for increased medical staff, among other initiatives. For more information on U.S. support for Mozambique’s efforts to combat COVID-19, visit this link.
In close collaboration with the Government of the Republic of Mozambique, the U.S. Government provides more than $500 million in annual assistance to improve the quality of education and healthcare, promote economic prosperity, and support the overall development of the nation.
Distributed by APO Group on behalf of U.S. Embassy in Mozambique.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
